4.5 Interaction with other medicinal products and other forms of interaction  
 No interaction studies have been performed.  
 Transient elevation of certain proinflammatory cytokines by epcoritamab may suppress CYP450 enzyme activities. On initiation of epcoritamab therapy in patients being treated with CYP450 substrates with a narrow therapeutic index, therapeutic monitoring should be considered.  
 
